Hot News

造福中低收入國 默沙東授權生產新冠學名藥 @ 2021-10-28T20: Back Hot News
Keyword:口服藥 默沙東 新冠
Concept:默沙東新冠口服藥歐盟 , 默沙東授權生產新冠口服藥學名藥
默沙東(MERCK)表示,105個中低收入國家將適用此免權利金授權。藥品專利聯盟(MEDICINES PATENT POOL, MPP)所遴選的藥廠,將得以生產學名藥版本默沙東實驗性抗病毒口服藥莫納皮拉韋(MOLNUPIRAVIR)。
美國藥廠默沙東(MERCK)與聯合國支持的非營利組織「藥品專利聯盟」(MPP)達成授權協議,允許多家藥廠生產旗下新冠口服藥「MOLNUPIRAVIR」,以擴大對中低收入國家的藥物供應。
英國金融時報、路透社報導,默沙東成為首批簽訂新冠療法免權利金授權協議的制藥廠,若MOLNUPIRAVIR獲得主管機關許可,其學名藥制造活動可望因而獲得提振。默沙東已跟數家印度制造商敲定授權協議,努力滿足全球高漲需求。
ACT-A計畫要求20國集團(G20)和其他WHO的贊助國在2022年9月之前提供228億美元的額外資金,用於購買並分配疫苗、藥物和檢測工具給貧窮國家,藉此縮小富裕國家和未開發國家所能取得的新冠醫藥資源差距;盡管文件中沒有明確表示要購買默沙東(MERCK)研發、日前申請緊急授權的新冠肺炎口服藥劑「MOUPIRAVIR」,但是《路透社》認為,這會是其中一種涵蓋於計畫采購內的藥物。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.